newsfilter
← Latest News
GlobeNewswire·

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

  • Turn Therapeutics Inc. (NASDAQ: TTRX) appointed Mr. Martin Dewhurst to its Board of Directors.
  • Mr. Dewhurst brings over 30 years of global life sciences leadership experience with a focus on mergers & acquisitions.
  • CEO Bradley Burnam stated the appointment supports a disciplined, M&A-focused strategy to expand the pipeline & accelerate value creation.
  • Mr. Dewhurst co-led McKinsey & Company's global life sciences practice & co-founded the McKinsey Health Institute.
  • Current roles include senior advisor to PJT Partners, external partner to Lightrock, & board member at Distalmotion.
  • He holds an undergraduate degree from the University of Oxford & an MBA from INSEAD.
  • Turn Therapeutics has received three FDA clearances for proprietary wound & dermatology formulations.
  • The company is advancing late-stage clinical programs in eczema & onychomycosis while pursuing thermostable vaccine delivery initiatives.